Handling of rescue and missing data affects synthesis and interpretation of evidence: The sodium-glucose cotransporter 2 inhibitor example

Annals of Internal Medicine

Volumn 159, Issue 4, 2013, Pages 285-288

  Stack, Catharine B ^a   Localio, A Russell ^b   Griswold, Michael E ^c   Goodman, Steven N ^d   Mulrow, Cynthia D ^e  

^a AMERICAN COLLEGE OF PHYSICIANS   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DATA PROCESSING; META ANALYSIS (TOPIC); METHODOLOGY; PRIORITY JOURNAL; RANDOMIZATION; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS;

DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; META-ANALYSIS AS TOPIC; PATIENT DROPOUTS; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84882243403     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-159-4-201308200-00009     Document Type: Article

References (20)

1. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes. A systematic review and meta-analysis. Ann Intern Med. 2013;159:262-74.
2. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383-94. [PMID: 21195583]
3. Higgins JP, Altman DG, Gøtzsche PC, Juüi P, Moher D, Oxman AD, et al; Cochrane Bias Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. [PMID: 22008217]
4. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol. 2011;64:407-15. [PMID: 21247734]
5. Panel on Handling Missing Data in Clinical Trials, National Research Council, eds. The Prevention and Treatment of Missing Data in Clinical Trials. Washington, DC: National Academies Pr; 2010.
6. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43. [PMID: 23425012]
7. U.S. Food and Drug Administration. FDA Briefing Document. NDA 202293. Dapagliflozin Tablets, 5 and 10 mg. Rockville, MD: U.S. Food and Drug Administration; 2011. Accessed at www.fda.gov/downloads/AdvisorysCommittee/CommitteesMeetingMaterials/drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm262994.pdf on 18 March 2013.
8. Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, et al; Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156:405-15. [PMID: 22431673]
9. Molenberghs G, Kenward MG. Missing Data in Clinical Studies. Hoboken, NJ: J Wiley; 2007:27-37.
10. Daniels MJ, Hogan JW. Missing Data in Longitudinal Studies: Strategies for Bayesian Modeling and Sensitivity Analysis. Boca Raton, FL: Chapman & Hall/ CRC; 2008.
11. Yuan Y, Little RJ. Meta-analysis of studies with missing data. Biometrics. 2009;65:487-96. [PMID: 18565168]
12. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. Hoboken, NJ: J Wiley; 2011.
13. Mallinckrodt CH, Clark WS, David SR. Type I error rates from mixed effects model repeated measures versus fixed effects ANOVA with missing values imputed via last observation carried forward. Drug Inf J. 2001;35:1215-25.
14. White IR, Carpenter J, Pocock SJ, Henderson RA. Adjusting treatment comparisons to account for non-randomized interventions: an example from an angina trial. Stat Med. 2003;22:781-93. [PMID: 12587105]
15. Small DS, Ten Have TR, Joffe MM, Cheng J. Random effects logistic models for analysing efficacy of a longitudinal randomized treatment with nonadherence. Stat Med. 2006;25:1981-2007. [PMID: 16220487]
16. Toh S, Hernań MA. Causal inference from longitudinal studies with baseline randomization. Int J Biostat. 2008;4. Article 22. [PMID: 20231914]
17. Toh S, Hernańdez-Diáz S, Logan R, Rossouw JE, Hernań MA. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med. 2010;152:211-7. [PMID: 20157135]
18. Frangakis CE, Rubin DB. Principal stratification in causal inference. Biometrics. 2002;58:21-9. [PMID: 11890317]
19. Institute of Medicine. Treatment of Posttraumatic Stress Disorder: An Assessment of the Evidence. Appendix D: Analysis and Interpretation of Studies With Missing Data. Washington, DC: National Academies Pr; 2008.
20. Molnar FJ, Man-Son-Hing M, Hutton B, Fergusson DA. Have lastobservation- carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review. Open Med. 2009;3: e31-50. [PMID: 19946392]